



---

**TO: All insurers authorized to write life & health insurance products in Florida, including those writing supplemental products**

The following information is provided as guidance to insurers about the form and rate filing process in Florida for life and health insurance products, mainly Patient Protection and Affordable Care Act (PPACA) compliant products in the small group and individual markets. This overview is intended to assist the industry in understanding the filing process and deadlines, as well as to provide insight into how the Office of Insurance Regulation (Office) will allocate resources to meet federal timeframes. In the event that new federal regulations or guidelines are implemented, this guidance may be subject to change.

Although the Office will continue to process other life and health filings unrelated to PPACA (e.g., long-term care, Medicare supplement, annuity products) during the May to August timeframe, companies are requested to delay making any non-essential filings of these types during this period to allow analysts time to focus on the PPACA filings.

### **PPACA Filing Deadlines**

Per the final United States Department of Health and Human Services (HHS) [Notice of Benefit and Payment Parameters for 2018](#) and guidance within the [2018 Letter to Issuers in the Federally-facilitated Marketplaces](#), the filing submission deadline for PPACA-compliant products (including stand-alone dental plans) in the individual and small group markets is **May 3, 2017**. *This deadline is applicable for products sold both on and off exchange.*

Additionally, the Office must complete its review of filings with Qualified Health Plans (QHP) in the risk pool by **August 21, 2017**. Filings will be processed in the order they are received, and there will be no “expedited” status granted to any filings.

### **Review Timeframe**

The Office is required by Section 627.410(2), Florida Statutes, to take action on a filing within thirty (30) days of receipt of the form and/or rate filing, with an option to extend this statutory review deadline by another fifteen (15) days. The anticipated filing volume and short review window will likely result in the Office requiring companies to respond very quickly to requests for information or explanations regarding a filing. Providing complete and clear information in a filing and responding quickly to Office requests will facilitate the timely review of all filings.

### **Information to be Filed**

The information requested in this notice should be submitted at the time of filing. Some of the information is not required to be initially submitted to make a complete filing. However, the Office may require it to be submitted after filing pursuant to Section 624.26(2), Florida Statutes, and Rule

69O-149.021(6)(c), Florida Administrative Code. In order to streamline the review process, the issuer is encouraged to submit the information at the time of filing.

Pursuant to Rules 69O-149.002 and 69O-191.051(1), Florida Administrative Code, changes made to a form shall be filed with the Office and the filing shall include a rate filing or an actuarial certification that the form change does not require a change of rates. In addition, according to the 2018 Letter to Issuers, an issuer must submit the Unified Rate Review Template for all single risk pool plans, including plans with rate increases, rate decreases, no rate change, and new plans. Therefore, a rate filing will be required for all PPACA-compliant products.

### Forms Information

Insurers should file all plan documents for the upcoming plan year. No forms revisions for the 2018 plan year will be accepted after the final federal approval deadline. Insurers should not file non-PPACA (transitional/grandfathered) plans in the same filing as PPACA-compliant plans.

The following is required for a form filing:

- Detailed Cover Letter
- Contract/Policy
- Application/Enrollment Form
- Certificate (if applicable)
- Schedule of Benefits (if separate document and not embedded in the policy/contract)
- Readability Certification
- Riders/Addendums/Endorsements (if applicable)
- A Sample Policy

The Office has developed worksheets to assist companies making PPACA-compliant form filings. In order to expedite the review process, the Office encourages companies to download, complete, scan and upload the applicable worksheet(s) as a part of the form filing submitted to the Office via I-File. The worksheets may be downloaded from the Office's [website](#). The worksheets may not contain all of the PPACA requirements. The Office offers these worksheets as guidance only and the use of them is voluntary.

### Rates Information

The Office is also taking into consideration the tight timeframe in the rate review process, and is thus providing a preliminary rate clarification letter for issuers to answer. Upon initial submission of the filing, please submit numbered responses to the following questions in a separate document.

### [Initial Filing Questions](#)

## Templates to be Submitted

An issuer should submit the following templates to the Office as part of an issuer's Florida filing:

- Plan Data Template\*
- Chronic Conditions Template (See Formulary Review for Certain Conditions)
- HIV/AIDS Template (See HIV/AIDS Formulary)
- Drug Attestation (See Drug Formulary Attestation)
- Federal QHP Plans and Benefits Template
- Federal Prescription Drug Template
- Federal Unified Rate Review Template
- Federal Crosswalk Template
- Federal Summary of Benefits and Coverage
- Federal Business Rules Template
- Federal Network ID Template
- Federal Essential Community Providers/Network Adequacy Template
- Federal Rate Data Template
- Federal Service Area Template

*\*The Plan Data Template will need to be populated during the I-File filing process. The template will be validated in I-File against Federal Templates. When filing, allow yourself sufficient time to correct any errors or issues which might arise during the validation process.*

## Drug Formulary Attestation

The Final Notice of Benefit and Payment Parameters for 2018 continues to charge the Office with the preliminary enforcement authority to monitor a plan's drug formulary and to ensure the plan's benefit design is not unfairly discriminatory. In order to facilitate the Office's review of a plan's drug formulary, an officer or director of the issuer may submit an attestation with its filing confirming the policy form's compliance with 45 C.F.R. § 156.122, regulating Prescription Drug Benefits, and 45 C.F.R. § 156.125, Prohibiting Discrimination, as well as an explanation of how the insurer has determined that its coverage of HIV/AIDS medications and medications for other chronic conditions (see next section below) is substantially similar to the safe harbor plan or is otherwise compliant with Florida and federal law.

The Office is prohibited from certifying a plan to be included on the Federally-facilitated Marketplaces if the Office knows that the plan employs a drug formulary discriminatory in benefit design, benefit implementation, or medical management techniques.

The attestation referenced above is available on the Office's website by clicking here: [Drug Formulary Attestation](#)

## **HIV/AIDS Formulary**

For the 2018 plan year, the Office will continue to monitor the coverage of medications for those living with HIV/AIDS. Sections 627.429 and 641.3007, Florida Statutes, specifically prohibits treating those living with HIV/AIDS less favorably than any other condition. Designing benefits or drug formularies that limit access to drug regimens for HIV or AIDS violates these statutes.

A health plan is required to be substantially similar in its scope of benefits to the state's benchmark plan and may not unfairly discriminate in benefit design, in the implementation of its benefit design, or medical management technique.

The Office will consider a health plan's formulary compliant with these provisions of Florida and federal law if the tiered formulary of HIV/AIDS medications is at least as favorable as the safe harbor plan.

The safe harbor referenced above is available on the Office's website by clicking here:

[HIV/AIDS Formulary Instructions](#)

[HIV/AIDS Formulary Template](#)

Compliance with the safe harbor guidelines is not mandatory. However, the Office is prohibited from certifying a plan to be included on the Federally-facilitated Marketplaces if the Office knows that the plan employs a drug formulary discriminatory in benefit design, benefit implementation or medical management techniques. Additionally, the Office will disapprove any plan it finds violates Sections 627.429, 641.3007, or 641.31(3)(c)6., Florida Statutes.

## **Formulary Review for Certain Conditions**

According to the 2018 Letter to Issuers in the Federally-facilitated Marketplaces, issuers must use the benchmark plan when designing their plans. Centers for Medicare & Medicaid Services (CMS) also cautioned issuers to avoid discouraging enrollment of individuals with chronic health needs, which may occur if an issuer places most or all drugs that treat a specific condition on the highest cost formulary drug tier. Enforcement of standards related to discriminatory benefit designs is largely conducted by the state. In its letter, CMS identified certain chronic conditions the state should monitor, including Bipolar Disorder, Breast Cancer, Diabetes, Hepatitis C, HIV/AIDS, Multiple Sclerosis, Prostate Cancer, Rheumatoid Arthritis, and Schizophrenia.

Please note that QHPs are required to cover at least one form of the prescription Naloxone in order to comply with the Essential Health Benefits (EHB) prescription drug count standard.

In an effort to streamline the filings and coordinate required information with federal agencies pursuant to Section 624.26, Florida Statutes, the Office has developed a template for issuers to complete and submit with each filing. For every QHP formulary, the template has a field for issuers to identify the number of drugs for each formulary tier for the respective chronic condition the drug treats. This information will enable the Office to determine whether it should make a required certification to include the plan on the Federally-facilitated Marketplaces. The Office is prohibited from including a plan on the Federally-facilitated Marketplaces if the Office knows that the plan

employs a drug formulary discriminatory in benefit design, benefit implementation, or medical management techniques.

The instructions and template for the formulary review referenced above is available on the Office's website by clicking here: [Chronic Conditions Template](#)

### **Experience Pooling**

In accordance with Section 627.410(6)(e)3., Florida Statutes, and Rule 69O-149.003(1)(a), Florida Administrative Code, the experience of all non-grandfathered health insurance policy forms in a rate filing that provide similar benefits, whether open or closed, shall be combined unless otherwise permitted. This requirement applies to health insurance policies, including dental policies.

### **Taxes and Fees**

The moratorium of the Health Insurer Tax set forth in PPACA Section 9010 and 26 C.F.R. § 57 for the 2017 plan year no longer applies for the 2018 plan year. Therefore, plans should reflect the tax in their rate filings.

### **Experience Reporting**

This year the Office has revised its experience exhibit to include a column for cost-sharing reduction payments received.

Please provide historical experience since 2014 on a *quarterly* basis. All experience exhibits should be in Excel with active formulas for all calculated values and projections. Historical and future Florida experience should be provided in the format outlined in Rule 69O-149.006(3)(b)23., Florida Administrative Code. An example of the recommended format can be found at: [Sample Experience Exhibit](#).

### **Rate Collection System**

Last year, the Office added a column for Formulary IDs that synchronized with the Federal Prescription Drug Template and simultaneously with the rate collection system. This year, metal-level specific network IDs have been added to the template. The Office also added separate copay and coinsurance columns in order to account for more complex plan designs.

*The data collection template is generated during the I-File filing process and must be completed before submitting the filing for review. When filing, allow yourself sufficient time to complete this information before the deadline.*

## **Guaranteed Renewable Insurance and Uniform Modifications of Coverage**

Changes to plans and products may be made only in accordance with the HHS Uniform Modification of Coverage regulations or the state and federal guaranteed renewability regulations.

If a change in coverage is not a Uniform Modification of Coverage, the guaranteed renewable provisions in Sections 627.6425, 627.6571, and 641.31074, Florida Statutes, will apply.

## **Transitional Policies**

On February 29, 2016, CMS extended the transitional policy for non-grandfathered coverage in the small group and individual health insurance markets to policy years beginning on or before October 1, 2017, provided that all transitional policies end by December 31, 2017.

The Office will work with any company that chooses to continue coverage in accordance with the transitional policy to facilitate the continuation of coverage for Floridians in accordance with the [February 29<sup>th</sup> CMS bulletin](#).

For questions related to any of the above information, please contact the following staff:

Eric Johnson – Chief Actuary & Director

850-413-5059

[Eric.Johnson@flor.com](mailto:Eric.Johnson@flor.com)

Craig Wright – Deputy Director of Life and Health Actuarial

850-766-6002

[Craig.Wright@flor.com](mailto:Craig.Wright@flor.com)

Betty Jo Pate – Deputy Director for Forms

850-413-5158

[Betty.Pate@flor.com](mailto:Betty.Pate@flor.com)

Shannon Doheny – Deputy Director for Legal Affairs

850-413-5110

[Shannon.Doheny@flor.com](mailto:Shannon.Doheny@flor.com)



**FLORIDA OFFICE OF  
INSURANCE REGULATION**